gh21
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 20, 2022 (NCT05183243)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06435455 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2024 | Chinese Academy of Medical Sciences, Suzhou Genhouse Bio Co., Ltd. |
| NCT06322095 | Phase 2 | Mar 22, 2024 | Suzhou Genhouse Bio Co., Ltd. |
| NCT06306456 | Phase 1/Phase 2 (Phase 2) | Mar 5, 2024 | Suzhou Genhouse Bio Co., Ltd. |
| NCT05183243 | Phase 1 | Feb 20, 2022 | Suzhou Genhouse Bio Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Genhouse Bio Co., Ltd. | For profit | 4 | 4 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1